Human Renal Proximal Tubule Epithelial Cells (RPTEC/TERT1) Modified to Express Drug Transporters A New Model for Toxicity Studies
This record is part of
a dataset collected by the EU Commission in June-September 2018
. Some of these links will therefore die out with time.
Please see the
overview of courses maintained by ETPLAS
or contact Norecopa for more information.
Owner/Developer: American Type Culture Collection (ATCC)
United States of America
19 October 2017
|Description:||Kidney membrane transporters are key to drug disposition and renal clearance. Primary renal proximal tubule epithelial cells (RPTEC) are the most physiologically relevant cell models, but lose OAT1 and OCT2 expression in culture. Primary RPTEC transiently expressing these transporters show large variations between production lots. Furthermore, cell line-based models either do not have the kidney tissue origination or are tumor-derived. This presentation will introduce transporter cell models using hTERT-immortalized RPTEC that stably overexpress the OAT1 or OCT2 gene. Our data show that these cell lines provide tissue-relevant results, improved consistency over time, and predictability for clinical trials.|
Optional / Voluntary
Students, Researchers, Regulators and policy-makers, Teachers and educators, Technicians, Managers, Scientific officers / Project managers, Professionals (e.g. veterinarians), General public
Academia, Industry, Governmental bodies, Contract Research Organizations (CROs), Consulting, SMEs
University (Bachelor), University (Master), University (Doctoral education), Postdoctoral (teaching and research), Continuing Professional Development
In vitro methods
Full coverage (a dedicated course)
|Details on the topic or technology covered:||
There is a lack of in vitro models that durably and correctly recapitulate kidney physiology
ATCC has created kidney cell models using hTERT-immortalized RPTEC that stably overexpress the OAT1 or OCT2 gene
hTERT-immortalized RPTEC provide kidney tissue-related results, improved consistency over time, and predictability for clinical trials
Did you find what you were looking for?Yes, I found it! No, I did not!
Thanks for your feedback! Please note that we cannot respond unless you supply your email address.
What are you looking for?
Please give us your feedback so we can improve the information on the page. Thank you in advance for your help. Please add your email address if you would like a reply.Please contact us by email if you have any questions.